George Colberg

Mr. Colberg co-founded Kalos Therapeutics in 2005.  Mr. Colberg has developed the corporate philosophy of Kalos, identified and worked to shape the strategy behind the primary products, and markets for Kalos. He has raised the seed round, series A round and grant financing.  Mr. Colberg recruited and retained the executive team and scientific advisory board and has had an active hand in the clinical development plan.  Mr. Colberg has investigated new compounds and constructs for potential licensing or acquisition and continues to explore new opportunities for Kalos.  His continuing role in the Company will be to provide the strategic vision, be active in the development of relationships that will lead to collaborations, promote corporate governance, assist in the establishment of corporate regulations and controls and preside over board level functions.  Mr. Colberg has experience in corporate finance and management. He was CEO of Primary Inc., a company dealing with issues related to The Stark legislation where he pioneered the plan for acquisitions and the business model initiating early efforts in personalized medicine electronic medical record meshed with patient data and billing and advanced use of diagnostics. Prior to that he was a Vice President at the Financial Group doing syndications and equity investment research. In this capacity Mr. Colberg was named Young Entrepreneur of the Year by Price Waterhouse.